Globus Medical, Inc. – Consensus ‘buy’ rating and 5.5% Upside Potential

Broker Ratings

Globus Medical, Inc. which can be found using ticker (GMED) have now 13 analysts in total covering the stock. The consensus rating is pointing to ‘buy’. The range between the high target price and low target price is between $115.00 and $85.00 calculating the average target price we see $97.85. Given that the stocks previous close was at $92.79 this would indicate that there is a potential upside of 5.5%. The day 50 moving average is $85.34 and the 200 day moving average is $72.29. The market cap for the company is 12.68B. The current share price for the company is: $93.12 USD

The potential market cap would be $13,370,801,894 based on the market consensus.

The company is not paying dividends at this time.

Other points of data to note are a P/E ratio of 150.19, revenue per share of $18.22 and a 4.73% return on assets.

Globus Medical, Inc. is a medical device company that develops and commercializes healthcare solutions. The Company’s product categories include Musculoskeletal Solutions and Enabling Technologies. Musculoskeletal Solutions consist primarily of implantable devices, biologics, accessories, and surgical instruments used in a range of spinal, orthopedic and neurosurgical procedures. Its spine products address the majority of conditions affecting the spine, including degenerative conditions, deformity, tumors, and trauma. It provides solutions that facilitate both open and minimally invasive surgery (MIS) techniques. It includes traditional fusion implants, such as pedicle screws and rod systems. Its orthopedic trauma solutions are designed to treat a variety of orthopedic fracture patterns and patient anatomies in the upper and lower extremities, as well as the hip. Enabling Technologies is comprised of imaging, navigation and robotics (INR) solutions for assisted surgery.

Share on:
Find more news, interviews, share price & company profile here for:

      Search

      Search